I refer the Hon. Member to the announcement made on the evaluation of newborn screening for spinal muscular atrophy by the Department on 16 July, which is available at the following link:

https://www.gov.uk/government/news/every-baby-in-england-to-get-life-saving-genetic-test-from-birth

In addition, the newborn heel prick test is routinely carried out by health visitors or community midwives on day five after birth.

Assessment of midwifery practice is undertaken locally by National Health Service providers through clinical governance, supervision, record-keeping standards, training, and professional regulation requirements.

Miscarriage can have a devastating impact on women and their families, and we are determined that they receive the support they need.

My Rt Hon. Friend, the Secretary of State for Health and Social Care, is chairing the Maternity and Neonatal Taskforce to develop a national action plan that will reform maternity and neonatal services to deliver lasting change for women, families, and their babies.

The taskforce will consider all aspects of those current services, including miscarriage care. Within this, we will carefully assess the findings from the Tommy’s Graded Model of Miscarriage Care pilot study as committed to in the Renewed Women’s Health Strategy.

HS England is responsible for commissioning the NHS Genomic Medicine Service (GMS). Genomic testing in the National Health Service in England is provided through the NHS GMS and the genomic testing nationally commissioned and funded by NHS England for patients in England is set out in the National Genomic Test Directory.

NHS England captures Patient Level Contract Monitoring (PLCM) data across the NHS GMS to facilitate a national approach to reporting and validating activity data and turnaround times for the genomics element of the pathway. NHS England holds quarterly assurance meetings with the NHS GMS to oversee delivery and publishes PLCM data on a quarterly basis on the NHS England website, at the following link:

https://www.england.nhs.uk/statistics/statistical-work-areas/genomic-testing-activity/

NHS England continues to develop this dataset, and in the future will develop the collecting and reporting of outcome data.

Pregnant women are offered at least two ultrasound scans during pregnancy, at 11 to 14 weeks and between 18 and 21 weeks. National Health Service trusts are measured against the NHS Fetal Anomaly Screening Programme standard for the 20-week screening scan. This standard requires providers to offer the scan between 18 weeks and zero days, and 20 weeks and six days of pregnancy. The screening pathway should be completed by 23 weeks and zero days of pregnancy.

I refer the Hon member to the answer provided on 16 July in response to Question 17458.

I refer the Hon member to the answer provided on 16 July in response to Question 17458.

Human papillomavirus (HPV) self-testing was launched in a gradual roll out nationally through the NHS Cervical Screening Programme from 25 August 2026. Individuals aged 30 to 65 years old who have been identified nationally as falling behind in their screening will be specifically invited by the programme to order an HPV self-test kit.

Currently, approximately 71% of people in Walsall eligible for cervical screening are up to date with their screening. People from the Walsall area who have been identified nationally to receive self-testing invitations will be starting to receive them now, as part of the gradual roll out.

NHS England is working with relevant partners to support awareness and understanding among those invited to take part in the programme. In addition, a community engagement project will be undertaken by the NHS Black Country Integrated Care Board, which may act as a basis for similar initiatives in other parts of the country.

No assessment has been made.

I refer the Hon. Member to the answer provided on 6 July in response to Question 13406.

I refer the Hon. Member to the answer provided on 6 July in response to Question 13406.

I refer the Hon Member to the answer given on 15 July to Question 16704.

Since 2013 local authorities in England have been legally responsible for commissioning the NHS Health Check programme as set out in the Local Authorities Functions Regulations 2013. The Government’s Public Health Grant to local authorities is used to enable its provision, with general practice being the most frequently commissioned by local authorities to provide the service.

The NHS Health Check provides a mechanism for supporting primary care in achieving several Quality and Outcomes Framework indicators.

There are currently no plans to further incentivise the delivery of NHS Health Checks.

The NHS Cervical Screening Programme is highly effective at preventing cancer as well as detecting disease early, primarily through the identification and treatment of high-risk human papillomavirus (HPV) and pre-cancerous changes.

On 25 August 2026, the National Health Service in England announced the roll out the new self-testing kits to encourage more women to complete their potentially lifesaving screening to detect HPV, which can increase the risk of cervical cancer.

NHS England and the UK Health Security Agency do not routinely report or publish HPV vaccination coverage data for post-school-age catch-up cohorts. Approaches to evaluating the impact of the 2025/26 general practice HPV vaccination catch-up campaign on vaccination uptake among eligible young people are currently being explored.

Health is a devolved matter, and cancer services in Scotland, Wales, and Northern Ireland are the responsibility of their respective administrations. The National Cancer Plan therefore applies to England only, while we continue to work closely with devolved administrations to share learning and best practice.

No formal assessment of the Making Every Contact Count impact on HPV vaccination or cervical screening is planned although we recognise its importance in encouraging uptake of vaccination and screening services. Uptake of HPV vaccination and coverage of cervical screening will continue to be monitored through established programme arrangements.

The information requested on women's health hubs is not held by the Department. Breast screening is delivered through the NHS Breast Screening Programme, which invites eligible women aged 50 to 71 years old every three years. Information on breast awareness and screening eligibility is available through the National Health Service website and the NHS App.

There are currently no plans to change the existing local surveillance arrangements for women at moderate and high risk of breast cancer.

Despite some recent misinformed media coverage, I can confirm to the Hon. Members that there has been no change to the policy in respect of prostate specific antigen (PSA) testing for men aged over 50 years old. Any such man who is concerned about prostate cancer, regardless of whether they have symptoms, remains free to make an appointment with their general practitioner, raise their concerns, and ask for a PSA test, exactly as they have done in the past. No impact assessment was therefore made when the guidance in this area was consolidated and updated in June, as there was no change in policy to assess.

The two main studies from the Cochrane review were included in the UK National Screening Committee modelling when they made their most recent recommendation regarding prostate cancer screening, and it should be noted that the Cochrane review came to the same statistical conclusions as the UK National Screening Committee regarding ‘mortality reduction", sometimes called lives saved, from PSA testing and subsequent treatment.

With regard to the next review of prostate cancer screening, I refer the Hon. Members to the article published by the UK National Screening Committee on 11 August 2026, which is available at the following link:

https://nationalscreening.blog.gov.uk/2026/08/11/the-uk-nscs-prostate-cancer-screening-model-will-remain-open-and-under-review/

Despite some recent misinformed media coverage, I can confirm to the Hon. Members that there has been no change to the policy in respect of prostate specific antigen (PSA) testing for men aged over 50 years old. Any such man who is concerned about prostate cancer, regardless of whether they have symptoms, remains free to make an appointment with their general practitioner, raise their concerns, and ask for a PSA test, exactly as they have done in the past. No impact assessment was therefore made when the guidance in this area was consolidated and updated in June, as there was no change in policy to assess.

The two main studies from the Cochrane review were included in the UK National Screening Committee modelling when they made their most recent recommendation regarding prostate cancer screening, and it should be noted that the Cochrane review came to the same statistical conclusions as the UK National Screening Committee regarding ‘mortality reduction", sometimes called lives saved, from PSA testing and subsequent treatment.

With regard to the next review of prostate cancer screening, I refer the Hon. Members to the article published by the UK National Screening Committee on 11 August 2026, which is available at the following link:

https://nationalscreening.blog.gov.uk/2026/08/11/the-uk-nscs-prostate-cancer-screening-model-will-remain-open-and-under-review/

Despite some recent misinformed media coverage, I can confirm to the Hon. Members that there has been no change to the policy in respect of prostate specific antigen (PSA) testing for men aged over 50 years old. Any such man who is concerned about prostate cancer, regardless of whether they have symptoms, remains free to make an appointment with their general practitioner, raise their concerns, and ask for a PSA test, exactly as they have done in the past. No impact assessment was therefore made when the guidance in this area was consolidated and updated in June, as there was no change in policy to assess.

The two main studies from the Cochrane review were included in the UK National Screening Committee modelling when they made their most recent recommendation regarding prostate cancer screening, and it should be noted that the Cochrane review came to the same statistical conclusions as the UK National Screening Committee regarding ‘mortality reduction", sometimes called lives saved, from PSA testing and subsequent treatment.

With regard to the next review of prostate cancer screening, I refer the Hon. Members to the article published by the UK National Screening Committee on 11 August 2026, which is available at the following link:

https://nationalscreening.blog.gov.uk/2026/08/11/the-uk-nscs-prostate-cancer-screening-model-will-remain-open-and-under-review/